Good evening :)
$
₹
Anixa Biosciences Inc

Anixa Biosciences Inc

ANIX

NASDAQ
Asset Logo

Anixa Biosciences Inc

ANIX

NASDAQ
$3.071.32% (+0.04)
$
₹
$3.071.32% (+0.04)
High
—
—
Low
—
—
Returns
—
—
Loading...
1D
1W
1M
3M
6M
1Y
3Y
5Y
Max

Healthcare

Biotechnology

Micro Cap

With a market cap of $114.0M the stock is ranked 4638

Key Metrics

Key Metrics

PE TTM
PE TTM

Close price divided by the earnings per share for the trailing twelve months

—
PB
PB

Close price divided by the book value per share at the end of the most recent quarter

7.18
EPS TTM
EPS TTM

Net profit earned per share over the trailing twelve months (sum of the last 4 quarters)

$-0.34
PEG Ratio
PEG Ratio

Price-to-Earnings (P/E) ratio divided by the forecasted annual earnings per share (EPS) growth rate over the next five years

—
Profit Margin
Profit Margin

Net profit divided by the total revenue for the most recent financial year

0%
Dividend Yield
Dividend Yield

Annual dividend per share for the trailing twelve months divided by the close price

—

Analyst Ratings & Forecast

Analyst Ratings & Forecast

Detailed Forecast Detailed Forecast 

Based on 3 analysts reports

Buy
3 analysts
Hold
0 analyst
Sell
0 analyst

Price Upside

+194.72%

Earnings Growth

+8.82%

Rev. Growth

—

See Detailed Forecast

Company Profile

Company Profile

Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines that are focused on critical unmet needs in oncology. Its therapeutics programs comprising the development of liraltagene autoleucel, a chimeric endocrine receptor-T cell therapy, a novel form of chimeric antigen receptor-T cell (CAR-T) technology that is focused on treating ovarian cancer. The company also engaged in the development of a vaccine against breast cancer; and the development of a vaccine discovery program to develop additional cancer vaccines to address intractable cancers, including high incidence malignancies in lung, colon, and prostate. Its vaccine technologies focus on the discovery of additional retired proteins that may be associated with other forms of cancer. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California.
Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines that are focused on critical unmet needs in oncology. Its therapeutics programs comprising the development of liraltagene autoleucel, a chimeric endocrine receptor-T cell therapy, a novel form of chimeric antigen receptor-T cell (CAR-T) technology that is focused on treating ovarian cancer. The company also engaged in the development of a vaccine against breast cancer; and the development of a vaccine discovery program to develop additional cancer vaccines to address intractable cancers, including high incidence malignancies in lung, colon, and prostate. Its vaccine technologies focus on the discovery of additional retired proteins that may be associated with other forms of cancer. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California.

Peers

Compare with peers Compare with peers 

Peers

Compare with peers Compare with peers 
AbbVie Inc
ABBV
AbbVie Inc
P/E Ratio
50.65
50.65
1Y Return
36.01%
36.01%
Buy Reco %
79.31
79.31
Amgen Inc
AMGN
Amgen Inc
P/E Ratio
27.73
27.73
1Y Return
50.65%
50.65%
Buy Reco %
35.29
35.29
Gilead Sciences Inc
GILD
Gilead Sciences Inc
P/E Ratio
—
—
1Y Return
42.33%
42.33%
Buy Reco %
78.57
78.57
Vertex Pharmaceuticals Inc
VRTX
Vertex Pharmaceuticals Inc
P/E Ratio
35.33
35.33
1Y Return
30.09%
30.09%
Buy Reco %
81.25
81.25
Regeneron Pharmaceuticals Inc
REGN
Regeneron Pharmaceuticals Inc
P/E Ratio
20.57
20.57
1Y Return
40.33%
40.33%
Buy Reco %
67.85
67.85
Compare with Peers

Forecast

Forecast

Price

Revenue

Earnings

Price Forecast

Price Forecast

Higher price growth forecast versus trailing 3-year CAGR
Compares analyst forecast growth with historical annualized growth.

The 12-month consensus target implies 194.72% growth, versus a trailing 3-year CAGR of 0.10%.

2026
Current$3.28Baseline
Analyst Target - 1 year
Target$9.67+194.72%

All values in $

202220232024202520262027$4.23$6.36$8.50Target+194.72%
2026
Current$3.28Baseline
Analyst Target - 1 year
Target$9.67+194.72%

All values in $

Earnings Per Share Forecast

Earnings Per Share Forecast

2025
Current$-0.34Baseline
Forecast for Oct 2026
High$-0.31+8.82%
Average$-0.31+8.82%
Low$-0.31+8.82%

All values in $

202120222023202420252026-0.42-0.46-0.32-0.39-0.34Low+8.82%Average+8.82%High+8.82%
2025
Current$-0.34Baseline
Forecast for Oct 2026
High$-0.31+8.82%
Average$-0.31+8.82%
Low$-0.31+8.82%

All values in $

Financials

Financials

Income

Balance Sheet

Cash Flow

-2.6
-2.5
-2.5
-2.6
Q4 2025
Q1 2026
Q2 2026
Q3 2026
Revenue
Net Income
Financial YearQ2 2024Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026Q2 2026Q3 2026
Total Revenue0000000000
Net Income-3.27-3.27-2.88-3.18-2.79-2.25-2.69-2.56-2.55-2.60
Net Profit Margin----------
See CostsAll values in $ Million

Peers

Peers & Comparison

Peers & Comparison

Comparing 2 stocks from
HealthcareBiotechnology

Valuation

Returns

Forecast

ScreenerCompare valuation on Screener
StockPE TTMPE TTMPBPBPEG RatioPEG Ratio
Anixa Biosciences Inc -7.18-
AbbVie Inc50.6550.450.58
Amgen Inc27.7321.332.75
ScreenerCompare valuation on Screener

Price Comparison

Price Comparison

Compare ANIX with any stock or ETF
Compare ANIX with any stock or ETF
Comparing from
ANIX
ABBV
AMGN
Loading...

Frequently asked questions

  1. Anixa Biosciences Inc (ANIX) share price today is $3.07 as of November 6, 2026 at 10:12 PM IST. The stock touched a day high of $3.09 and a day low of $3.00.

  2. Anixa Biosciences Inc stock trades on NASDAQ under the ticker symbol ANIX.

  3. Anixa Biosciences Inc's market capitalization is $114.02M as of November 6, 2026 at 10:12 PM IST.

  4. Anixa Biosciences Inc's price-to-earnings (P/E) ratio is N/A as of November 6, 2026.

  5. Anixa Biosciences Inc's price-to-book (P/B) ratio is 7.18 as of November 6, 2026.

  6. Yes, You can buy Anixa Biosciences Inc shares from India through Tickertape, via our partnership with ViewTrade IFSC under the IFSCA Global Access framework, subject to RBI’s Liberalised Remittance Scheme (LRS) limits.

  7. Indian investors can buy Anixa Biosciences Inc shares in three steps: 1. Search Anixa Biosciences Inc on the Tickertape app and tap Invest. 2. Complete your one-time digital KYC. 3. Fund your account and buy from as low as $1 via fractional shares.

  8. Since Anixa Biosciences Inc trades in USD, an Indian investor's INR returns depend on both the stock's price movement and the USD-INR exchange rate. If the rupee depreciates against the dollar, INR returns are boosted beyond the stock's USD return; if the rupee appreciates, INR returns are reduced.

  9. Indian investors can start investing in Anixa Biosciences Inc (ANIX) shares from as little as $1 through fractional ownership on Tickertape - for example, $10 buys approximately 3.2573 shares at the current price of $3.07.

Loading...